Ranibizumab 0.5mg

DRUG11 trials

Conditions

Age-related Macular DegenerationBranch Retinal Vein OcclusionCentral Retinal Vein OcclusionChoroidal NeovascularisationChoroidal NeovascularizationDiabetesDiabetes MellitusDiabetic Macular Edema

Phase 1

Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab

CompletedNCT01471691

Hanscom, Thomas, M.D.Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Macular Edema

Start: 2011-11-30End: 2014-02-28Updated: 2015-04-29

Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration

CompletedNCT01926977

Arshad KhananiNeovascular Age-Related Macular Degeneration

Start: 2013-09-30End: 2014-05-31Updated: 2016-03-03

Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration

CompletedNCT02140151

Southern California Desert Retina Consultants, MCAge-related Macular Degeneration

Start: 2014-09-17End: 2020-07-09Updated: 2022-08-25

Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration

CompletedNCT02302989

Leonard Feiner, MD, PhDAge-related Macular Degeneration

Start: 2015-05-31End: 2018-07-31Updated: 2018-08-28

Phase 2

Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen

CompletedNCT01037348

NovartisChoroidal Neovascularisation

Start: 2010-01-31End: 2012-05-31Updated: 2016-04-19

MIcrodoses of raNIbizumab in Diabetic MAcular Edema (MINIMA-2)

CompletedNCT01112085

Especialistas en Retina Medica y Quirurgica Grupo de InvestigacionDiabetic Macular Edema

Start: 2010-04-30End: 2014-06-30Updated: 2014-06-16

A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)

CompletedNCT03499223

OxurionDiabetes Mellitus, Diabetic Retinopathy, Macular Edema

Start: 2018-04-20End: 2019-07-18Updated: 2019-08-02

Phase 3

Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

CompletedNCT01922102

Novartis PharmaceuticalsVisual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)

Start: 2013-09-11End: 2016-09-14Updated: 2019-06-24

Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD

CompletedNCT01948830

Novartis PharmaceuticalsAge-related Macular Degeneration, Choroidal Neovascularization

Start: 2013-12-17End: 2015-11-19Updated: 2017-04-17

Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase

TerminatedNCT02032173

Novartis PharmaceuticalsDiabetes, Macular Degeneration, Macular Edema

Start: 2014-05-19End: 2015-04-29Updated: 2020-10-22

A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss

CompletedNCT05520177

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Branch Retinal Vein Occlusion

Start: 2022-12-27End: 2024-09-23Updated: 2025-12-18

Related Papers

Effect of posterior vitreous detachment on treat-and-extend versus monthly ranibizumab for neovascular age-related macular degeneration